Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Digestive Diseases and Sciences
Erschienen in: Digestive Diseases and Sciences 12/2012

01.12.2012 | Review

Endoscopic Management of Barrett’s Esophagus: Advances in Endoscopic Techniques

verfasst von: Ali Azarm, Ismet Lukolic, Meenal Shukla, Ronald Concha-Parra, Frank Gress

Erschienen in: Digestive Diseases and Sciences | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Abstract

Barrett’s esophagus (BE) is a well-known premalignant condition that can be associated with the development of dysplasia and adenocarcinoma. In the past, esophagectomy was the standard treatment for patients with BE with high grade dysplasia (HGD) and early cancer (EC). However, esophagectomy is not necessarily the only treatment response to HGD and EC anymore. Over the past decade, a number of endoscopic therapies have been developed for management of BE. These include endoscopic mucosal resection, thermal ablation techniques that use laser irradiation, multipolar electrocoagulation, argon plasma coagulation, photodynamic therapy, and the recently developed cryotherapy and radiofrequency ablation.
Literatur
1.
Barrett NR. Chronic peptic ulcer of the esophagus and ‘oesophagitis’. Br J Surg. 1950;38:175–182.PubMedCrossRef
2.
Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–831.PubMedCrossRef
3.
Van Sandick JW, van Lanschot JJ, Kuiken BW, Tytgat GN, Offerhaus GJ, Obertop H. Impact of endoscopic biopsy surveillance of Barrett’s oesophagus on pathological stage and clinical outcome of Barrett’s carcinoma. Gut. 1998;43:216–222.PubMedCrossRef
4.
Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–146.PubMedCrossRef
5.
Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008;67:394–398.PubMedCrossRef
6.
Jensen FH, Pedersen L, Drewes AM, Sorensen HT, Jensen PF. Incidence of adenocarcimoa among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375–1383.CrossRef
7.
Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology. 2001;120:1607–1619.PubMedCrossRef
8.
Heitmiller RF, Redmond M, Hamilton SR. Barrett’s esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg. 1996;224:66–71.PubMedCrossRef
9.
Sharma P. Controversies in Barrett’s esophagus: management of high grade dysplasia. Semin Gastrointest Dis. 2001;12:26–32.PubMed
10.
Ruol A, Zaninotto G, Costantini M, et al. Barrett’s esophagus: management of high-grade dysplasia and cancer. J Surg Res. 2004;117:44–51.PubMedCrossRef
11.
Korst RJ, Altorki NK. High grade dysplasia: surveillance, mucosal ablation, or resection? World J Surg. 2003;27:1030–1034.PubMedCrossRef
12.
Pera M, Trastek VF, Carpenter HA, Allen MS, Deschamps C, Pairolero PC. Barrett’s esophagus with high-grade dysplasia: an indication for esophagectomy? Ann Thorac Surg. 1992;54:199–204.PubMedCrossRef
13.
Edwards MJ, Gable DR, Lentsch AB, Richardson JD. The rationale for esophagectomy as the optimal therapy for Barrett’s esophagus with high-grade dysplasia. Ann Surg. 1996;223:585–589; discussion 589–591.
14.
Konda VJ, Ross AS, Ferguson MK, et al. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett’s esophagus overestimated? Clin Gastroenterol Hepatol. 2008;6:159–164.PubMedCrossRef
15.
Collard JM. High-grade dysplasia in Barrett’s esophagus. The case for esophagectomy. Chest Surg Clin N Am. 2002;12:77–92.PubMedCrossRef
16.
Falk GW, Rice TW, Goldblum JR, Richter JE. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett’s esophagus with high-grade dysplasia. Gastrointest Endosc. 1999;49:170–176.PubMedCrossRef
17.
Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347:1662–1669.PubMedCrossRef
18.
Stein HJ, Hutter J, Feith M, von Rahden BH. Limited surgical resection and jejunal interposition for early adenocarcinoma of the distal esophagus. Semin Thorac Cardiovasc Surg. 2007;19:72–78.PubMedCrossRef
19.
Banki F, Mason RJ, DeMeester SR, et al. Vagal-sparing esophagectomy: a more physiologic alternative. Ann Surg. 2002;236:324–335; discussion 335–336.
20.
Schembre DB, Huang JL, Lin OS, Cantone N, Low DE. Treatment of Barrett’s esophagus with early neoplasia: a comparison of endoscopic therapy and esophagectomy. Gastrointest Endosc. 2008;67:595–601.PubMedCrossRef
21.
O’Riordan JM, Tucker ON, Byrne PJ, et al. Factors influencing the development of Barrett’s epithelium in the esophageal remnant postesophagectomy. Am J Gastroenterol. 2004;99:205–211.PubMedCrossRef
22.
Pohl H, Sonnenberg A, Strobel S, et al. Endoscopic versus surgical therapy for early cancer in Barrett's esophagus: a decision analysis. GIE. 2009;70:623–631.
23.
Stein HJ, Feith M, Mueller J, Werner M, Siewert JR. Limited resection for early adenocarcinoma in Barrett’s esophagus. Ann Surg. 2000;232:733–742.PubMedCrossRef
24.
Holscher AH, Bollschweiler E, Schneider PM, Siewert JR. Early adenocarcinoma in Barrett’s oesophagus. Br J Surg. 1997;84:1470–1473.PubMedCrossRef
25.
Feith M, Stein HJ, Siewert JR. Pattern of lymphatic spread of Barrett’s cancer. World J Surg. 2003;27:1052–1057.PubMedCrossRef
26.
Sharma P, Falk GW, Sampliner R, Jon Spechler S, Wang K. Management of nondysplastic Barrett’s esophagus: where are we now? Am J Gastroenterol. 2009;104:805–808.PubMedCrossRef
27.
Choudhary A, Szary NM, Kuwajima VK, et al. Endoscopic interventions for Barrett's esophagus with low-grade dysplasia to prevent progression: a meta-analysis of randomized controlled trials. Gastrointest Endosc. 2010;71:AB173–AB174.CrossRef
28.
Wani S, Puli SR, Shaheen NJ, et al. Esophageal adenocarcinoma in Barrett’s esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol. 2009;104:502–513.PubMedCrossRef
29.
Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2006;4:566–572.PubMedCrossRef
30.
Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368–378.PubMedCrossRef
31.
Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288.PubMedCrossRef
32.
Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ. A cost-utility analysis of ablative therapy for Barrett’s esophagus. Gastroenterology. 2009;136:2101–2114.PubMedCrossRef
33.
Hemminger LL, Panossian AM, Duran C, et al. Procedural trends in endoscopic ablation and resection for esophageal dysplasia and carcinoma. Gastrointest Endosc. 2010;71:AB178.CrossRef
34.
Wang K. Endoscopic treatment for Barrett's esophagus and early esophageal cancer. J Gastrointest Surg. 2010;14:946–947.PubMedCrossRef
35.
Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett’s esophagus. Gastroenterology. 2000;118:670–677.PubMedCrossRef
36.
Ciocirlan M, Lapalus MG, Hervieu V, et al. Endoscopic mucosal resection for squamous premalignant and early malignant lesions of the esophagus. Endoscopy. 2007;39:24–29.PubMedCrossRef
37.
May A, Gossner L, Pech O, et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett’s oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol. 2002;14:1085–1091.PubMedCrossRef
38.
Ell C, May A, Pech O, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett’s cancer). Gastrointest Endosc. 2007;65:3–10.PubMedCrossRef
39.
Esaki M, Matsumoto T, Hirakawa K, et al. Risk factors for local recurrence of superficial esophageal cancer after treatment by endoscopic mucosal resection. Endoscopy. 2007;39:41–45.PubMedCrossRef
40.
Giovannini M, Bories E, Pesenti C, et al. Circumferential endoscopic mucosal resection in Barrett’s esophagus with high-grade intraepithelial neoplasia or mucosal cancer. Preliminary results in 21 patients. Endoscopy. 2004;36:782–787.PubMedCrossRef
41.
Peters FP, Kara MA, Rosmolen WD, et al. Endoscopic treatment of high-grade dysplasia and early stage cancer in Barrett’s esophagus. Gastrointest Endosc. 2005;61:506–514.PubMedCrossRef
42.
Buttar NS, Wang KK, Lutzke LS, Krishnadath KK, Anderson MA. Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett’s esophagus. Gastrointest Endosc. 2001;54:682–688.PubMed
43.
May A, Gossner L, Pech O, et al. Intraepithelial high-grade neoplasia and early adenocarcinoma in short-segment Barrett’s esophagus (SSBE): curative treatment using local endoscopic treatment techniques. Endoscopy. 2002;34:604–610.PubMedCrossRef
44.
Manner H, May A, Pech O, et al. Early Barrett’s carcinoma with “low-risk” submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol. 2008;103:2589–2597.PubMedCrossRef
45.
Sharma P, Jaffe PE, Bhattacharyya A, Sampliner RE. Laser and multipolar electrocoagulation ablation of early Barrett’s adenocarcinoma: long-term follow-up. Gastrointest Endosc. 1999;49:442–1446.PubMedCrossRef
46.
Dulai GS, Jensen DM, Cortina G, Fontana L, Ippoliti A. Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett’s esophagus. Gastrointest Endosc. 2005;61:232–240.PubMedCrossRef
47.
Barham CP, Jones RL, Biddlestone LR, Hardwick RH, Shepherd NA, Barr H. Photothermal laser ablation of Barrett’s oesophagus: endoscopic and histological evidence of squamous re-epithelialisation. Gut. 1997;41:281–284.PubMedCrossRef
48.
Weston AP, Sharma P. Neodymium:yttrium-aluminum garnet contact laser ablation of Barrett’s high grade dysplasia and early adenocarcinoma. Am J Gastroenterol. 2002;97:2998–3006.PubMedCrossRef
49.
Schulz H, Miehlke S, Antos D, et al. Ablation of Barrett’s epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole. Gastrointest Endosc. 2000;51:659–663.PubMed
50.
Attwood SE, Lewis CJ, Caplin S, Hemming K, Armstrong G. Argon beam plasma coagulation as therapy for high-grade dysplasia in Barrett’s esophagus. Clin Gastroenterol Hepatol. 2003;1:258–263.PubMedCrossRef
51.
May A, Gossner L, Gunter E, Stolte M, Ell C. Local treatment of early cancer in short Barrett’s esophagus by means of argon plasma coagulation: initial experience. Endoscopy. 1999;31:497–500.PubMedCrossRef
52.
Pereira-Lima JC, Busnello JV, Saul C, et al. High power setting argon plasma coagulation for the eradication of Barrett’s esophagus. Am J Gastroenterol. 2000;95:1661–1668.PubMedCrossRef
53.
Morris CD, Byrne JP, Armstrong GR, Attwood SE. Prevention of the neoplastic progression of Barrett’s oesophagus by endoscopic argon beam plasma ablation. Br J Surg. 2001;88:1357–1362.PubMedCrossRef
54.
Byrne JP, Armstrong GR, Attwood SE. Restoration of the normal squamous lining in Barrett’s esophagus by argon beam plasma coagulation. Am J Gastroenterol. 1998;93:1810–1815.PubMedCrossRef
55.
Pedrazzani C, Catalano F, Festini M, et al. Endoscopic ablation of Barrett’s esophagus using high power setting argon plasma coagulation: a prospective study. World J Gastroenterol. 2005;11:1872–1875.PubMed
56.
Pinotti AC, Cecconello I, Filho FM, Sakai P, Gama-Rodrigues JJ, Pinotti HW. Endoscopic ablation of Barrett’s esophagus using argon plasma coagulation: a prospective study after fundoplication. Dis Esophagus. 2004;17:243–246.PubMedCrossRef
57.
Van Laethem JL, Cremer M, Peny MO, Delhaye M, Deviere J. Eradication of Barrett’s mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut. 1998;43:747–751.PubMedCrossRef
58.
Van Laethem JL, Jagodzinski R, Peny MO, Cremer M, Deviere J. Argon plasma coagulation in the treatment of Barrett’s high-grade dysplasia and in situ adenocarcinoma. Endoscopy. 2001;33:257–261.PubMedCrossRef
59.
Johnston MH, Eastone JA, Horwhat JD, Cartledge J, Mathews JS, Foggy JR. Cryoablation of Barrett’s esophagus: a pilot study. Gastrointest Endosc. 2005;62:842–848.PubMedCrossRef
60.
Kerstetter DL, H F. Endoscopic cryoablation of Barrett’s with high grade dysplasia: a single center case series. Gastrointest Endosc. 2009;69:AB260–AB261.
61.
Shaheen NJ, Greenwald BD, Dumot JA, et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett’s esophagus with high grade dysplasia. Gastrointest Endosc. 2009;69:AB357.CrossRef
62.
Canto MI, Gorospe EC, Shin EJ. Carbon dioxide (CO2) cryotherapy is a safe and effective treatment of Barrett’s esophagus (BE) with HGD/intramucosal carcinoma. Gastrointest Endosc. 2009;69:AB341.CrossRef
63.
Flores A, G RS, Chung DS, et al. Barrett’s esophagus eradication by radiofrequency and cryoablation. Gastrointest Endosc. 2009;69:AB256.
64.
Wolfsen HC. Present status of photodynamic therapy for high-grade dysplasia in Barrett’s esophagus. J Clin Gastroenterol. 2005;39:189–202.PubMedCrossRef
65.
Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett’s esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc. 2005;62:488–498.PubMedCrossRef
66.
Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with photofrin in Barrett’s high-grade dysplasia. Gastrointest Endosc. 2007;66:460–468.PubMedCrossRef
67.
Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett’s esophagus: follow-up in 100 patients. Gastrointest Endosc. 1999;49:1–7.PubMedCrossRef
68.
Hage M, Siersema PD, van Dekken H, et al. 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett’s oesophagus: a randomised trial. Gut. 2004;53:785–790.PubMedCrossRef
69.
Pech O, Gossner L, May A, et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett’s cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc. 2005;62:24–30.PubMedCrossRef
70.
Van Laethem JL, Peny MO, Salmon I, Cremer M, Deviere J. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett’s oesophagus. Gut. 2000;46:574–577.PubMedCrossRef
71.
Sharma VK, Wang KK, Overholt BF, et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett’s esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc. 2007;65:185–195.PubMedCrossRef
72.
Chennat J, Ross AS, Konda VJ, et al. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management. Gastrointest Endosc. 2009;70:417–421.PubMedCrossRef
73.
Ganz RA, Utley DS, Stern RA, Jackson J, Batts KP, Termin P. Complete ablation of esophageal epithelium with a balloon-based bipolar electrode: a phased evaluation in the porcine and in the human esophagus. Gastrointest Endosc. 2004;60:1002–1010.PubMedCrossRef
74.
Gossner L, May A, Stolte M, Seitz G, Hahn EG, Ell C. KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett’s esophagus. Gastrointest Endosc. 1999;49:8–12.PubMedCrossRef
75.
Ragunath K, Krasner N, Raman VS, Haqqani MT, Phillips CJ, Cheung I. Endoscopic ablation of dysplastic Barrett’s oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness. Scand J Gastroenterol. 2005;40:750–758.PubMedCrossRef
76.
Vargo JJ. Clinical applications of the argon plasma coagulator. Gastrointest Endosc. 2004;59:81–88.PubMedCrossRef
77.
Manner H, Rabenstein T, Braun K, et al. What should we do with the remainder of the Barrett’s segment after endoscopic resection of early Barrett’s cancer? Gastrointest Endosc. 2010;71:AB175.
78.
Dumot JA. Successful training in gastrointestinal endoscopy. Gastrointest Endosc. 2009;70:635–644.
79.
Greenwald BD. Endoscopic spray cryotherapy for esophageal cancer: safety and efficacy. Gastrointest Endosc. 2010;71:686–693.PubMedCrossRef
80.
Sreenarasimhaiah J, Singh S. Utility of endoscopic ultrasound to determine the depth of cryospray ablation therapy in dysplastic Barrett’s esophagus. Gastrointest Endosc. 2010;71:AB315.CrossRef
81.
Ortner MA, Zumbusch K, Liebetruth J, et al. Is topical delta-aminolevulinic acid adequate for photodynamic therapy in Barrett’s esophagus? A pilot study. Endoscopy. 2002;34:611–616.PubMedCrossRef
82.
Grant WE, Hopper C, MacRobert AJ, Speight PM, Bown SG. Photodynamic therapy of oral cancer: photosensitisation with systemic aminolaevulinic acid. Lancet. 1993;342:147–148.PubMedCrossRef
83.
Prosst RL, Wolfsen HC, Gahlen J. Photodynamic therapy for esophageal diseases: a clinical update. Endoscopy. 2003;35:1059–1068.PubMedCrossRef
84.
Sanchez A, Reza M, Blasco AJ, Callejo D. Effectiveness, safety, and cost-effectiveness of photodynamic therapy in BE: a systemic review. Dis Esophagus. 2010;23:633–640.PubMedCrossRef
85.
Prasad GA, Wang KK, Buttar NS, et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett’s esophagus. Gastroenterology. 2007;132:1226–1233.PubMedCrossRef
86.
Prasad GA, Wang KK, Buttar NS, Wongkeesong LM, Lutzke LS, Borkenhagen LS. Predictors of stricture formation after photodynamic therapy for high-grade dysplasia in Barrett’s esophagus. Gastrointest Endosc. 2007;65:60–66.PubMedCrossRef
87.
Vij R, Triadafilopoulos G, Owens DK, Kunz P, Sanders GD. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett’s esophagus. Gastrointest Endosc. 2004;60:739–756.PubMedCrossRef
88.
Overholt B, Dean P, Galanko J, Lightdale C. Does Ablative therapy for BE affect the depth of subsequent esophageal biopsy as compared with controls. J Clin Gastroenterol. 2010;44:676–681.PubMedCrossRef
89.
Hubbard N, Velanovich V. Endoscopic endoluminal radiofrequency ablation of Barrett’s esophagus in patients with fundoplications. Surg Endosc. 2007;21:625–628.PubMedCrossRef
90.
Roorda AK, Marcus SN, Triadafilopoulos G. Early experience with radiofrequency energy ablation therapy for Barrett’s esophagus with and without dysplasia. Dis Esophagus. 2007;20:516–522.PubMedCrossRef
91.
Hernandez JC, T F, Reicher S, et al. Frequency of buried Barrett’s metaplasia after BARRX ablation for intestinal metaplasia with or without dysplasia. GIE. 2007; 65:AB11.
92.
Sharma V, K H, Mclaughlin R, et al. Successful circumferential ablation of Barrett’s esophagus (BE) with low grade dysplasia (LGD) using the HALO-360 ablation system: one-year follow-up of the AIM-LGD pilot trial. Gastrointest Endosc. 2006;63:AB127.
93.
Smith CD, Bejarano PA, Melvin WS, Patti MG, Muthusamy R, Dunkin BJ. Endoscopic ablation of intestinal metaplasia containing high-grade dysplasia in esophagectomy patients using a balloon-based ablation system. Surg Endosc. 2007;21:560–569.PubMedCrossRef
94.
Ganz R, Overholt G, Panjehpour M, et al. Treatment of Barrett’s esophagus and high-grade dysplasia using the HALO-360 ablation system: a multi-center experience. Gastrointest Endosc. 2006;63:AB124.CrossRef
95.
Gondrie JJ, P F, Curvers WL, et al. Radiofrequency ablation of Barrett’s esophagus containing high-grade dysplasia. Gastrointest Endosc. 2007;65:AB135.CrossRef
96.
Pouw RE, Gondrie JJ, Sondermeijer C, et al. Novel combined modality therapy for Barrett’s esophagus containing high-grade dysplasia: endoscopic mucosal resection followed by circumferential and focal ablation using the HALO system. Gastrointest Endosc. 2007;65:AB111.CrossRef
97.
Shaheen NJ, S P, Overholt BF, Linghtdale CJ, Wolfsen HC, Sampliner RE. A randomized, multicenter, sham-controlled trial of radiofrequency ablation (RFA) for subjects with Barrett’s esophagus (BE) containing dysplasia: interim results of the aim dysplasia trial. Gastroenterology. 2008;134:A-37.CrossRef
98.
Ganz RA, Overholt BF, Sharma VK, et al. Circumferential ablation of Barrett’s esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc. 2008;68:35–40.PubMedCrossRef
99.
Fleischer D, Overholt B, Sharma V, Reymunde A, Kimmey M, et al. Endoscopic radiofrequency ablation for Barrett’s esophagus. Gastrointest Endosc. 2010;71:AB117.CrossRef
100.
Dunkin BJ, Martinez J, Bejarano PA, et al. Thin-layer ablation of human esophageal epithelium using a bipolar radiofrequency balloon device. Surg Endosc. 2006;20:125–130.PubMedCrossRef
101.
Ackroyd R, Tam W, Schoeman M, Devitt PG, Watson DI. Prospective randomized controlled trial of argon plasma coagulation ablation vs. endoscopic surveillance of patients with Barrett’s esophagus after antireflux surgery. Gastrointest Endosc. 2004;59:1–7.PubMedCrossRef
102.
Sampliner RE. Endoscopic ablative therapy for Barrett’s esophagus: current status. Gastrointest Endosc. 2004;59:66–69.PubMedCrossRef
103.
Gondrie JJ, R A, Sondermeijer C, et al. Balloon-based circumferential ablation followed by focal ablation of Barrett’s esophagus containing high grade dysplasia effectively removes all genetic alterations. Gastroenterology. 2007;132:A-64.
104.
Krishnadath KK, Wang KK, Taniguchi K, et al. Persistent genetic abnormalities in Barrett’s esophagus after photodynamic therapy. Gastroenterology. 2000;119:624–630.PubMedCrossRef
105.
106.
Lyday W. Radiofrequency ablation of Barrett's esophagus: outcomes of 429 patients from a multicenter community practice registry. Endoscopy. 2010;42:272–278.PubMedCrossRef
107.
Inadomi J, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ. A cost utility analysis of ablative therapy for BE. Gastroenterology. 2009;136:2101–2114, e1–6.
108.
Shinoura S, Chang K, Iwashita T, Lee J, Mathusamy R. Are there factors that predict which patients undergoing radiofrequency ablation of Barrett’s esophagus will require prolonged ablation therapy? Gastrointest Endosc. 2010;71:AB172.CrossRef
109.
Leao P, Goers T, Pierce R, Dunst C, Swanstrom L. Short term outcome of concomitant antireflux surgery with BARRx ablation for Barrett’s esophagus. Gastrointest Endosc. 2010;71:AB178.CrossRef
110.
Vaccaro B, Gonzalez S, Abrams J, et al. Detection of Barrett’s esophagus after initial complete response with radiofrequency ablation. Gastrointest Endosc. 2010;71:AB182.CrossRef
111.
Seewald S, Ang TL, Gotoda T, Soehendra N. Total endoscopic resection of Barrett esophagus. Endoscopy. 2008;40:1016–1020.PubMedCrossRef
112.
Kantsevoy SV, Adler DG, Conway JD, et al. Endoscopic mucosal resection and endoscopic submucosal dissection. Gastrointest Endosc. 2008;68:11–18.PubMedCrossRef
113.
Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008;57:1200–1206.PubMedCrossRef
114.
Herrero LA, Pouw RE, Weusten BL, Bergman J. Multi-band mucosectomy in Barrett’s esophagus: a prospective registration of 1,060 resections in 243 procedures. Gastrointest Endosc. 2010;71:AB127.CrossRef
115.
Sayana H, W S, Keighley JD, et al. Endoscopic mucosal resection (EMR) as a diagnostic tool in Barrett’s esophagus (BE) patients with high-grade dysplasia (HGD) and early esophageal adenocarcinoma (EAC): a systematic review. Gastroenterology. 2008;134:A-724.CrossRef
116.
Shami VM, Villaverde A, Stearns L, et al. Clinical impact of conventional endosonography and endoscopic ultrasound-guided fine-needle aspiration in the assessment of patients with Barrett’s esophagus and high-grade dysplasia or intramucosal carcinoma who have been referred for endoscopic ablation therapy. Endoscopy. 2006;38:157–161.PubMedCrossRef
117.
Pouw R. Efficacy of RFA combined with endoscopic resection for BE with early neoplasia. Clin J Gastroenterol Hepatol. 2010;8:23–29.CrossRef
118.
Lopes CV, Hela M, Pesenti C, et al. Circumferential endoscopic resection of Barrett’s esophagus with high-grade dysplasia or early adenocarcinoma. Surg Endosc. 2007;21:820–824.PubMedCrossRef
119.
Soehendra N, Seewald S, Groth S, et al. Use of modified multiband ligator facilitates circumferential EMR in Barrett’s esophagus (with video). Gastrointest Endosc. 2006;63:847–852.PubMedCrossRef
120.
Lewis J, Rubenstein J, Singal A, Piraka C. Factors associated with esophageal stricture development following endoscopic mucosal resection for neoplastic Barrett’s esophagus. Gastrointest Endosc. 2010;71:AB324.CrossRef
121.
Kakushima N, Yahagi N, Fujishiro M, Kodashima S, Nakamura M, Omata M. Efficacy and safety of endoscopic submucosal dissection for tumors of the esophagogastric junction. Endoscopy. 2006;38:170–174.PubMedCrossRef
122.
Deprez P, Piessevaux H, Aouattah T, Yeung R, Sempoux C, Jouret-Mourin A. ESD in Barrett’s esophagus, high grade dysplasia and mucosal cancer. Gastrointest Endosc. 2010;71:AB126.CrossRef
123.
Pouw R, Bisschops R, Pech O, Ragunath K, Weusten B, et al. Safety outcome of balloon-based circumferential radiofrequency ablation after focal endoscopic resection of early Barrett’s neoplasia in 118 patients. Gastrointest Endosc. 2010;71:AB126.CrossRef
124.
Spechler SJ, Sharma P, Souza R, et al. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140:1084–1091.PubMedCrossRef
Metadaten
Titel
Endoscopic Management of Barrett’s Esophagus: Advances in Endoscopic Techniques
verfasst von
Ali Azarm
Ismet Lukolic
Meenal Shukla
Ronald Concha-Parra
Frank Gress
Publikationsdatum
01.12.2012
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 12/2012
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2279-0

Weitere Artikel der Ausgabe 12/2012

Digestive Diseases and Sciences 12/2012 Zur Ausgabe

Original Article

Is Endoscopic Ultrasound Needed as an Add-on Test for Gallstone Diseases Without Choledocholithiasis on Multidetector Computed Tomography?

Original Article

Single-Operator Wire-Guided Cannulation Technique Enables Easier Cannulation of Endoscopic Retrograde Cholangiopancreatography

Stanford Multidisciplinary Seminars

Tube to Freedom: Use of a Venting Jejunostomy in a Patient with Chronic Intestinal Pseudo-Obstruction

Review

Glucocorticoid Receptor Gene Polymorphisms and Glucocorticoid Resistance in Inflammatory Bowel Disease: A Meta-Analysis

Original Article

Hepatitis C Virus-Associated Primary Hepatocellular Carcinoma in Non-cirrhotic Patients

Editorial

Methanogenesis in Irritable Bowel Syndrome: A Lot of Hot Air?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise